MIYUN, China - s4story -- Recently, Beilu Pharma received the "Drug Registration Certificate" for its Vonoprazan Fumarate Tablets, approved and issued by the National Medical Products Administration (NMPA).

Vonoprazan fumarate is a potassium-competitive acid blocker (P-CAB) that suppresses gastric acid secretion and helps prevent injury to the upper gastrointestinal mucosa. It is primarily indicated for the treatment of reflux esophagitis and, in combination with appropriate antibiotics, for the eradication of Helicobacter pylori. According to Menet, sales of vonoprazan fumarate tablets in China (covering both urban and county-level public hospitals) reached approximately RMB 973 million in 2025. The product is included in Category B of the National Reimbursement Drug List (NRDL).

More on S For Story

• Gregg Roman Releases New Literary Espionage Thriller - The Closing Window
• Search Is Broken. Curated Discovery Is the Future
• 20 Ways to Save Money Running a Van
• How Fortress Law Group Turned a DUI Arrest in Ohio Into a Full Acquittal at Trial
• Breaking the Silence: Tour Sparks National Conversation on Men's Mental Health and Domestic Abuse

Vonoprazan fumarate tablets have been approved as a Class 4 chemical drug, deemed to have passed the consistency evaluation for generic drug quality and efficacy. This approval further enriches Beilu Pharma's product portfolio and is expected to enhance its market competitiveness.

Contact Information:
Beijing Beilu Pharmaceutical Co., Ltd.
https://www.beilupharma.com/
yanglm@beilupharma.com